Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2021

View Archived Issues

A virus-specific nanobody lowers latent viral loads in HCMV-infected cells

Clinical hold extended for ORTHO-R phase I/II study

Genexine describes anti-TAA, anti-PD-L1, TNFRSF9 ligand fusion proteins

Sumitomo Dainippon Pharma Oncology patents serine/threonine kinase Nek2 inhibitors

New SREBP inhibitors identified at Capulus Therapeutics

Shanghai Bowei Biological Technology, collaborators divulge polynucleotides for expressing HPV 51L1

KIN-001 for COVID-19 shows preclinical antiviral, anti-inflammatory and antifibrotic activity

APP gene mutation causes autosomal dominant Alzheimer's disease

Salicylanilide compounds show promise for treating COVID-19

Improved serum metabolic profile and symptoms in patients with ALS treated with ILB

AAV gene therapy targeting CaMKII protects retinal ganglion cells, preserves vision

ACMT reports on patients becoming ill from use of ivermectin for COVID-19

Bavarian Nordic studies ABNCoV2 as COVID-19 booster vaccine in phase II

FDA clears IND for clinical trials of siroquine for newly diagnosed GBM

Phase I data reported for GDC-3280 in healthy subjects

Cytokine-induced JAK/STAT signaling plays role in cachexia

KalVista gains clinical trial approvals for phase II trial of KVD-824 for HAE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...